Age-related macular degeneration (AMD), which results in progressive retinal damage, stands as the primary reason for vision loss among individuals aged 65 and older. While nutritional supplements were previously the only option, patients now have access to a revolutionary, FDA-approved advancement: the Valeda Light Delivery System, utilizing photobiomodulation (PBM) light therapy.
By targeting the retina—the vital component of the eye that transmits visual information to the brain—the Valeda system provides a new therapeutic pathway for those managing this progressive disease.
What is Dry Age-Related Macular Degeneration (Dry AMD)?
Comprising roughly 85–90% of all macular degeneration diagnoses, Dry AMD is a persistent, age-related condition. It specifically impacts the macula, the retinal region necessary for clear central vision. The disease is characterized by the slow deterioration of light-sensitive macular cells, which is frequently linked to the buildup of protein and lipid deposits known as drusen.
As the condition advances, patients may experience distorted sight or a total loss of central vision, making essential daily tasks—such as reading or identifying faces—increasingly difficult. Despite its often gradual progression, Dry AMD continues to be a primary driver of lasting visual impairment.
What is Valeda?
Valeda is an innovative treatment that uses precise wavelengths of red and infrared light to address the cellular processes involved in dry macular degeneration (AMD). Through photobiomodulation (PBM), Valeda stimulates mitochondrial activity, supports healthy cell metabolism, and helps reduce inflammation and cell death. This advanced therapy works to slow the progression of dry AMD, improve vision, and even decrease drusen—the small yellow deposits that build up in the retina.
Treatment Details
Valeda uses a cutting-edge light delivery system to emit red and infrared light. The treatment is non-invasive, safe, and performed through multiple sessions over a few weeks.
No Pain | No Drops/Dilation | No Injection
Patients undergoing Valeda therapy can expect a comfortable and non-invasive experience. Here’s how it works:
• Before Treatment: No special preparation is needed. Patients just need to simply remove glasses or contact lenses.
• During Treatment: Patients are seated in front of the unit and guided through a short light exposure session that is less than 5 minutes per eye.
• After Treatment: Some patients may experience a temporary afterimage known as photo stress, which usually resolves within 15–30 seconds. Patients can resume normal activities immediately after treatment and no patch/bandage is needed.
• Treatment Schedule: Most patients complete a series of 9 treatment sessions over 3-5 weeks. After the initial series, follow-up treatments are typically scheduled every 4 months.
• FDA Approval: Valeda is the first FDA-approved device for dry macular degeneration (AMD) and the first treatment specifically for intermediate dry AMD. It represents a groundbreaking advancement for patients with this condition.
Is PBM light therapy right for you?
Valeda is an excellent option for patients with dry macular degeneration (AMD) who have drusen or non-central geographic atrophy. However, this treatment is not recommended for individuals with wet AMD or for those who have advanced vision loss caused by central macular atrophy.
Safety
The Valeda Light Delivery System technology delivered to the retina is generally safe with minimal side effects. Studies report no damage to the eye or its photoreceptors.
Clinical Results
Valeda light therapy has been extensively studied in clinical trials and has shown promising results. After two years of treatment, patients experienced a mean improvement of one line in visual acuity on the ETDRS eye chart, compared to those who did not receive treatment.
